playandearncryptogame|葵花药业：复方聚乙二醇（3350）电解质散获得上市许可受理

News summary

Sunflower Pharmaceutical: Compound Polyethylene Glycol (3350) Electrolyte Powder obtained listing license accepted Securities Times e Company Newsplayandearncryptogame, Kuihua Pharmaceutical (002737) announced on the evening of May 5 that its wholly-owned subsidiary Harbin Kuihua Pharmaceutical Co., Ltd.(referred to as "Harbin Kuihua") recently received a receipt from the State Drug Administrationplayandearncryptogame...

Newsletter text

Sunflower Pharmaceutical: Compound Polyethylene Glycol (3350) Electrolyte Powder was accepted for marketing authorization Securities Times Company e News, Sunflower Pharmaceutical (002737) announced on the evening of May 5 that its wholly-owned subsidiary Harbin Sunflower Pharmaceutical Co., Ltd.(referred to as "Harbin Sunflower") Recently received the "Acceptance Notice" issued by the State Food and Drug Administration on the application for registration and marketing authorization of Compound Polyethylene Glycol (3350) Electrolyte Powder, and proposed the indications (or functional indications): Used to treat chronic constipation in children aged 1 to 11 years and fecal impaction in children aged 5 to 11 years.